Guardians of immunity: the role of tumour-draining lymph node in cancer immunity (opens in new tab)

The success of immunotherapies in cancer has changed the landscape of cancer research. The tumour-draining lymph node (TDLN) is emerging as an organ specific target to enhance the efficacy and minimize the toxicity of immunotherapies; this approach is based on the TDLN being the first lymph node to encounter metastatic tumour cells and various tumour-derived factors. Both anti-tumour and immunosuppressive T cells can originate from the TDLNs. Accumulating evidence has shown that immunosuppres...